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Objective: We examine the lifetime cost-effectiveness of treatment with fluticasone propio-
nate/salmeterol (500/50 mg) compared with no maintenance treatment in COPD in the US.
Methods: A decision-analytic model was developed to estimate lifetime costs and outcomes asso-
ciatedwithfluticasonepropionate/salmeterol 500/50mg treatment, salmeterol 50 mg, andflutica-
sone propionate 500 mg compared to no maintenance treatment in treating COPD from a third-
party US payer perspective. The patient population was similar to that of the TORCH clinical trial.
Model structure and inputswereobtained frompublished literatureand clinical trial data. All costs
are presented in 2006 US dollars. Outcomes included cost per life year (LY) saved and cost per
quality-adjusted life year (QALY) gained. Costs and outcomes were discounted at 3% annually.
Univariate and multivariate sensitivity analyses were conducted to assess model robustness.
Results: Compared to no maintenance treatment, treatment with fluticasone propionate/salme-
terol 500/50 mg results in a lifetime incremental cost-effectiveness ratio (ICER) of $33,865/QALY.
Treatment with salmeterol 50 mg was found to have an ICER of $20,797/QALY. These results are
robust to changes in input parameters. Fluticasone propionate 500 mg was dominated by no treat-
ment, though the results were not robust to changes in parameters.
Conclusions: Treatment of COPD with fluticasone propionate/salmeterol 500/50 mg appears to be
cost-effective ($50,000/QALY) compared to no maintenance treatment. Similarly, salmeterol
50 mg may be cost-effective compared to no maintenance treatment. Compared with no mainte-
nance treatment, fluticasone propionate 500 mg was effective in reducing number of exacerba-
tions, but failure to differentiate from no maintenance treatment in mortality resulted in it
being dominated in the base case.
ª 2008 Elsevier Ltd. All rights reserved.arnshaw, 200 Park Offices Drive, PO Box 12194, Research Triangle Park, NC 27709, USA. Tel.: þ1 919
(S.R. Earnshaw).
8 Elsevier Ltd. All rights reserved.
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12e17Chronic obstructive pulmonary disease (COPD) is a term to
describe conditions including chronic bronchitis and
emphysema. COPD is currently the fourth leading cause of
mortality and morbidity in the United States (US), with an
estimated number of deaths per year of over 100,000.1 In
2004, an estimated $20.9 billion in direct medical costs
(and an additional $16.3 billion in indirect costs) were
incurred due to COPD.2 It has been estimated that roughly
1.5 million emergency department visits and over 700,000
hospitalizations are incurred annually due to exacerbations
of COPD.2
Current guidelines recommend pharmacological treat-
ment for patients withmoderate COPD, starting with regular
use of a long-acting bronchodilator plus a short-acting
bronchodilator as needed for acute symptoms. Patients with
severe to very severe COPD and recurrent exacerbationsmay
add an inhaled corticosteroid.3,4 The use of long-acting
bronchodilators and inhaled corticosteroids (often referred
to as ‘controller’ or ‘maintenance’ medications) assists in
reducing symptoms and the need for rescuemedications and
increases the time between exacerbations.5,6
Several retrospective analyses have suggested that in
addition to reducing symptoms and improving the quality of
life, controller medications also improve survival in COPD,
although this has not been reported in all analyses.7e10 A
recently published prospective study, the Towards a Revo-
lution in COPD Health (TORCH) project, was a 3-year,
placebo-controlled randomized clinical trial with mortality
as a primary endpoint that examined the survival benefits
of fluticasone propionate (500 mg) and salmeterol (50 mg)
either independently or combined in a single inhaler.11 The
combination showed an adjusted mortality hazard ratio of
0.811 (p-valueZ 0.03) and salmeterol had a hazard ratio of
0.857 (p-valueZ 0.11) over a 3-year period as compared to
placebo. Fluticasone propionate did not have any survival
advantage at 3 years as compared to placebo. The combi-
nation of fluticasone propionate and salmeterol is the first
pharmacologic treatment that has been shown to have
a survival benefit in COPD and raises the possibility that this
treatment is cost-effective compared to no maintenance
treatment in terms of both survival and quality-adjusted
life years (QALYs).Severe C
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Figure 1 Modehave been published. To date, no published
economic analyses have considered mortality by treat-
ment drug. We hypothesize that introducing the admin-
istration of fluticasone propionate/salmeterol (500/50 mg)
as a treatment for COPD will have a substantial impact on
drug costs, medical resource costs, QALYs Was defined
easlier and possibly cost-effectiveness. The goal of this
paper is to estimate the cost-effectiveness of treating
patients with COPD with fluticasone propionate/salme-
terol (500/50 mg), fluticasone propionate (500 mg), or
salmeterol (50 mg) compared to no maintenance treat-
ment (i.e., no controller therapy).
Subjects and methods
Overview
A Markov model was developed to examine the cost-
effectiveness of treating COPD patients with the Diskus
Accuhaler containing either fluticasone propionate/sal-
meterol (500/50 mg) in combination, fluticasone propionate
500 mg alone, or salmeterol 50 mg alone as compared to no
maintenance treatment. The patient population is assumed
to have similar age characteristics as that of a typical
patient population with moderate to very severe COPD
observed in the published literature and as estimated from
the TORCH study.11 These patients are assumed to have
additional characteristics similar to those observed in the
clinical trial setting. These characteristics include but are
not limited to: male and female outpatients age 40e80
years of age with a baseline FEV1< 60% of predicted
normal, established clinical history of COPD, current or
former smokers with a smoking history of at least 10 pack-
years, poor reversibility of airflow obstruction, an increase
of FEV1 with the use of 400 mg of albuterol of less than 10%
of the predicted value for that patient, and baseline (pre-
bronchodilator) FEV1/FVC ratio  70%.11
Model structure
The model, presented in Fig. 1, is a Markov-based
model and is programmed in Microsoft Excel. PatientsOPD
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states:
 Moderate COPD: patients have 50% FEV1 percent
predicted <60%;
 Severe COPD: patients have 30%  FEV1 percent pre-
dicted  50%; or
 Very severe COPD: patients have FEV1 percent pre-
dicted <30%.
COPD severity was defined according to the TORCH study
definitions. These definitions are similar to those of the
American Thoracic Society (ATS) guidelines.18 Upon
entering the model, patients are prescribed one of the
four maintenance treatments as examined within the
TORCH clinical trial: fluticasone propionate/salmeterol
500/50 mg (FSC) combination, fluticasone propionate
500 mg (FP), salmeterol 50 mg (SAL) or no maintenance
treatment. Patients may transition annually to the next
severe health state or stay in the current health state.
From any health state, patients may transition to Death in
any year. Within a year, patients may experience
a moderate exacerbation (an exacerbation requiring
systemic corticosteroids and/or antibiotics), severe
exacerbation (an exacerbation requiring hospitalization),
or no exacerbation (event-free).
The model estimates lifetime per patient costs,
outcomes, and incremental cost-effectiveness ratios.
Costs are reported in 2006 US dollars, and all costs and
outcomes are discounted at 3% per annum.19 This analysis
was performed from a third-party payer perspective and
relevant costs and outcomes were incorporated into the
analysis.
Input parameters
The model considers various parameters in order to
estimate total costs, life years, exacerbations, and
QALYs. Input parameters were taken from a variety of
sources including clinical trial data and other published
studies,11e14,20 and include the following critical
elements.
Transition probabilities
Transitions between moderate, severe, and very severe
COPD were obtained as used in previous analyses.13,21
These data were based on data from the Lung Health
Study.22 These data are assumed to be similar between
all comparators as, until recently, there has been little
evidence that COPD treatments have a substantial
effect on the rate of FEV1 decline except in the first
six to twelve months of treatment. Celli et al. have
very recently reported an analysis of the TORCH data
and showed difference between treatments in the
annual rate of decline that reached statistical signifi-
cance.23 However, these data are difficult to translate
into a model. Sin et al.13 present a non-drug specific
progression from moderate to severe COPD and severe
to very severe COPD as 0.74% and 2.48% every three
months, respectively. We convert these transition
probabilities to annual probabilities by assuminga constant hazard of progression. With this, the annual
probability of transitioning between health states is
presented in Table 1.
Exacerbation risk
Patients in the model are able to experience moderate and
severe exacerbations. Moderate exacerbations were
defined as exacerbations requiring systemic corticoste-
roids, and severe exacerbations were defined as exacer-
bations requiring hospitalization.11 The number of total and
severe exacerbations expected to be experienced by ‘no
maintenance treatment’ (i.e., placebo) patients and the
rate ratios of exacerbations for each treatment were
obtained from the TORCH clinical trial11 and may be seen in
Table 1. Exacerbations were assumed to occur at similar
rates between COPD severity health states. This assumption
was examined in sensitivity analysis. Mean duration of
exacerbation was taken from the published literature and
estimated as 14 and 28 days from moderate and severe
exacerbations, respectively.13 Duration of exacerbations
was assumed to be similar between treatments.
Mortality risk
In the first 3 years of the model, results of TORCH were used
to estimate the treatment-specific effect on mortality.
Specifically, the adjusted probability of all-cause mortality
at 3 years for patients taking no maintenance treatment
was taken as base. These data, rather than the unadjusted
probability of all cause mortality, were used in the model as
they account for between group differences in covariates
such as age, sex, smoking status, region, baseline FEV1, and
body mass index. This 3-year probability was converted to
an annual probability assuming a constant hazard and then
adjusted for differences in mortality that may be observed
among patients with differing levels of FEV1 percent pre-
dicted as reported by Sin et al.13 Reductions in mortality for
patients on FSC, FP, and SAL were estimated by applying
the hazard ratios versus placebo from TORCH. Baseline
mortality and rate ratios along with 95% confidence inter-
vals are reported in Table 1.
TORCH only reports mortality for the 3-year clinical trial
period. Baseline mortality beyond 3 years is assumed to
increase annually as a function of age. This increase was
estimated from an exponential increase in age-specific, all-
cause mortality from the U.S. National Vital Statistics.24
Patients on treatment were assumed to incur the full
mortality benefits of treatment as long as they stayed on
treatment. As it is possible that this full benefit may not be
observed in patients post year 3, we examine the impact of
attenuation of benefit (i.e., smaller mortality reduction)
over time post year 3 in sensitivity analysis.
Costs
The cost of treating a COPD exacerbation can be resource
intensive. The model considers the marginal cost due to
having a moderate and/or severe exacerbation. The cost
of a moderate exacerbation was estimated from published
literature and clinical opinion. The cost of moderate
exacerbation incurs the cost of outpatient physician visits,
emergency department visits, laboratory tests, miscella-
neous supplies, X-rays, antibiotics, and corticosteroids.
Table 1 Base case values and ranges of plausible values.
Model parameter Base case value Plausible range [p-value] Source
Discount rate
Costs 0.03 0, 0.05, and 0.07 19
Outcomes 0.03 0, 0.05, and 0.07 19
Baseline annual
risk of total exacerbations
1.13 þ/20% 11
Rate ratio of total exacerbation
(versus placebo)
11
No maintenance therapy 1.00 e
FSC 0.75 0.69e0.81 [<0.001]
FP 0.82 0.76e0.89 [<0.001]
SAL 0.85 0.78e0.93 [<0.001]
Baseline risk of severe exacerbation 0.19 þ/20% 11
Rate ratio of severe exacerbation
(versus placebo)
11
No maintenance therapy 1.00 e
FSC 0.83 0.71e0.98 [0.028]
FP 0.88 0.74e1.03 [0.104]
SAL 0.82 0.69e0.96 [0.016]
Duration of exacerbations (days) 13
Moderate 14 þ/20%
Severe 28 þ/20%
Baseline annual
mortality risk
11,13
Moderate COPD 0.035 þ/20%
Severe COPD 0.056 þ/20%
Very severe COPD 0.084 þ/20%
Annual mortality
hazard ratio (versus placebo)
11
No maintenance therapy 1.000 e
FSC 0.811 0.670e0.982 [0.03]
FP 1.056 0.883e1.264 [0.55]
SAL 0.857 0.710e1.035 [0.11]
Health state utility values 14
Moderate COPD 0.755 þ/20%
Severe COPD 0.748 þ/20%
Very severe COPD 0.549 þ/20%
Exacerbation utility multipliers 12
Moderate 0.85 þ/20%
Severe 0.50 þ/20%
Disease Transition Probabilities 13
Moderate COPD to severe COPD 0.0293 þ/20%
Severe COPD to very
severe COPD
0.0956 þ/20%
Cost-effectiveness of fluticasone propionate/salmeterol 15Specifically, we assumed 90% of patients experiencing
a moderate exacerbation would seek initial care for that
exacerbation via an unscheduled outpatient physician
visit. The other 10% would seek initial care via an emer-
gency department visit [clinical opinion, Feb 14, 2008]. Of
all patients, 80% would get an X-ray, 100% would be
prescribed an antibiotic, 50% would be prescribed a corti-
costeroid [clinical opinion, Feb 14, 2008], and 50% of
patients seeking initial care via an unscheduled outpatient
visit would have a follow up visit. Resource use cost was
obtained using the RBRVS.25 Unit costs for each resourceare presented in Table 2 along with sources and assump-
tions. The total cost of a moderate exacerbation is esti-
mated to be $243.29.
In an analysis of the NDCHealth Hospital Patient Level
Database, Stanford et al.20 examined ‘‘the resource
utilization, health outcomes, and costs associated with
hospital care among patients treated in the emergency
department and/or hospital for COPD in the US’’.20
Specifically, they estimated the average cost of an exac-
erbation for patients who visited an emergency depart-
ment and were not admitted, were admitted and required
16 S.R. Earnshaw et al.an intensive care unit (ICU) stay with no intubation, were
admitted and required intubation with no ICU stay, were
admitted and required ICU stay with intubation, and had
a standard non-complicated admission. The cost of
a severe exacerbation was estimated as the weighted
average of the cost of patients who were admitted. Since
Stanford et al.20 report these average costs in 2001 US
dollars, this value is inflated to 2006 dollars using the
medical Consumer Price Index (CPI)26 for a cost of $8858
(95% CI: $2814, $14,901). These costs include facility care,
laboratory tests, room and board, and medication use. In
addition, the model assumes that 50% of patients experi-
encing a severe exacerbation hospitalization incur an
additional follow-up outpatient visit. The cost for time
with no exacerbation was assumed to be standard COPD
treatment and thus assumed to be zero additional costs to
patients.
Annual drug costs were estimated to be $2155 for FSC,
$543 for FP, and $999 for SAL based on wholesale
acquisition cost (WAC) pricing from the Red Book.27
These costs are based on dosing observed within
TORCH.11 Rate of adherence of 88% was assumed for all
treatments as seen in TORCH.11 All costs, when appro-
priate, were adjusted to 2006 US dollars using the
medical CPI.26
Utility weights
Utility weights were applied from those previously used
in a COPD decision model. Utility weights range from 0.0
to 1.0, where a utility value of 1.0 represents perfect
health and a value of 0.0 represents death. These utility
values are used to estimate QALYs by multiplying the
number of life years within a particular health state by
the health state’s utility weight.
Utility weights by disease severity were obtained from
a study by Borg et al.14 (2004) in which 0.755 was esti-
mated for 50% <FEV1 percent predicted <80%, 0.748 for
30% <FEV1 percent predicted <50%, and 0.549 for FEV1
percent predicted <30%.14 Patient’s utilities were
decreased when exacerbation occurred. Oostenbrink
et al.12 estimated a 15% decrease in utility for patients
experiencing a moderate exacerbation,28 and a 50%
decrease in utility for patients experiencing a severe
exacerbation.29Table 2 Unit costs values.
Cost parameter Base case val
Outpatient visit $95.50
X-ray $35.24
Emergency department visit $656.11a
Antibiotics $18.23
Corticosteriods $2.52
a Stanford et al.20 report an average cost of a COPD exacerbation tr
value is inflated to 2006 dollars using the medical CPI.26 (2007 US $:Model calculations
The model is designed to calculate the following outcomes:
costs (treatment drug, other medical, and total); life years;
QALYs; moderate and severe exacerbations; incremental
cost per life year gained; and incremental cost per QALY
gained. The incremental cost per QALY in this analysis is
compared to the commonly accepted threshold of $50,000
in the US even though recent studies support the use of
a higher cost-effectiveness threshold.30e32
Sensitivity analysis
To test the robustness of the model assumptions and
specific parameters, we examined the effect of changing
several parameters in one-way sensitivity analyses.
Parameters analyzed include the baseline probability of
exacerbation; rate ratio of exacerbation for each treat-
ment; duration of moderate and severe exacerbation;
baseline mortality for each COPD severity; mortality
hazard ratio for each treatment; cost of moderate and
severe exacerbations; utility weights for health states;
exacerbation disutility multipliers; transitions between
health states; and drug costs. The effect of varying
individual parameters was examined using plausible
ranges of values (Table 1) from the literature, 95%
confidence intervals were available, or by varying the
estimates by up to 20% in each direction. Attenuation of
the impact of treatment on mortality was examined by
assuming a linear decline in efficacy over a range of 0e10
years starting at year 4 in the model.
In addition to one-way sensitivity analyses, we also per-
formed probabilistic sensitivity analyses (second-order
Monte Carlo simulation). The parameters varied in these
analyses are similar to those in the one-way sensitivity
analyses. We assumed that parameter estimates followed
a gamma distribution for the following parameters: duration
and cost of moderate and severe exacerbation; baseline risk
of exacerbation; exacerbation rate ratios; drug-specific
hazard ratio of exacerbation and mortality; and drug cost.
A beta distribution was assumed for baseline mortality by
COPD health state, utility weights, and transition probabili-
ties. Analyses were run 10,000 times in order to capture
stability in the results for each relevant scenario. Scatterue Source/assumption
CPT code: 9921425
CPT code: 7102025
20
Two week
course of amoxicillin 500 mg three
times daily18,27
Two week
course of prednisone 20 mg twice
daily18,27
eated via an emergency department visit of $571 (2001 US$). This
$656, 95% CI: $74, $1239).
35,402
35,425
38,307
29,958
26,501
71,133
23,889
38,732
41,230
33,066
71,972
36,575
31,596
30,197
32,456
32,306
31,892
36,740
39,723
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Figure 2 One-way sensitivity analysis: effect of parameter variation on the incremental cost per QALY for fluticasone propio-
nate/salmeterol (500/50 mg) compared to no maintenance treatment.
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effectiveness acceptability curves were created.Results
Base case analysis results
Treating with FSC results in total remaining lifetime medical
costs of $42,019 compared to $23,727 for FP, $29,439 for SAL,
and $18,986 for no maintenance treatment. Patients on FSC,
FP, and SAL offset some of the additional drug costs with
a reduction in other medical costs (i.e., $2012, $2600, and
$2272 for patients treated with on FSC, FP, and SAL versus no
maintenance treatment, respectively).
Patients treated with FSC, FP, and SAL incur a substan-
tial reduction in exacerbations and hospital days compared
to patients on no maintenance treatment (Table 2). In
addition, patients treated with FSC and SAL can expect to
gain 0.94 and 0.68 life years and 0.69 and 0.50 QALYs.
However, based on the results of TORCH, patients on FP
may see a reduction in life years and QALYs of 0.24 and
0.16, respectively compared to patients on no mainte-
nance treatment.
Based on the data above, treating with FSC compared
with no maintenance treatment is found to have an incre-
mental cost-effectiveness ratio of $33,865 per additional
QALY gained. Compared to no maintenance treatment, SALand FP are cost-effective at an incremental cost per QALY
of $20,797 and dominated, respectively. Assuming an
acceptability threshold of $50,000 per QALY gained,30e32
the results suggest that treatment with FSC is cost-effec-
tive compared to no maintenance therapy.
Sensitivity analyses
Fig. 2 illustrates one-way sensitivity of the incremental cost
per QALY of FSC compared to no maintenance treatment to
variations in several model parameters. The incremental
cost per QALY was most sensitive to the relative risk of
mortality for FSC (versus no maintenance treatment) in
patients with moderate COPD and the duration of time over
which FSC has full efficacy. Specifically, if the FSC relative
risk of mortality for patients with moderate COPD is greater
than 0.916 or the duration of full efficacy of FSC is less than
5 years, the incremental cost per QALY of FSC compared to
no maintenance treatment is expected to be greater than
$50,000. The incremental cost per QALY is somewhat
sensitive to changes in FSC drug costs, FSC relative risks of
mortality for severe and very severe COPD patients, and
utility for moderate COPD. However, the incremental cost
per QALY never becomes greater than the $50,000
threshold.
The effect of discount rate was also considered.
Specifically, we examined the incremental cost-effective-
ness of FSC compared to PLA assuming a discount rate for
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Figure 3 Results of probabilistic sensitivity analysis: incre-
mental cost-effectiveness scatter plot of fluticasone propio-
nate/salmeterol (500/50 mg) versus no maintenance treatment.
18 S.R. Earnshaw et al.costs and outcomes of 0%, 5%, and 7%. The undiscounted
incremental cost per QALY is found to be $29,187. The
incremental cost per QALY for discount rates of 5% and 7%
are $37,220 and $40,718, respectively.
Probabilistic sensitivity analysis for the comparison of
FSC and no maintenance treatment was performed using
a second-order Monte Carlo simulation. We ran 10,000
simulations for the probabilistic sensitivity analysis. This
approach has been demonstrated to be large enough to
ensure model robustness. Fig. 3 presents a scatter plot of
the 10,000 simulations for patients on FSC compared to no
maintenance treatment. As can be seen in the figure, 77.6%
of the simulations resulted in an incremental cost per QALY
less than $50,000.
Discussion
Our analysis indicates that treatment with FSC is cost-
effective compared to no maintenance treatment.
Increases in costs incurred due to the administration of FSC
are somewhat offset by decreases in expected lifetime
medical costs associated with COPD. More importantly,
patients treated with FSC are expected to see a significant
improvement in life years and QALYs. Patients treated with
SAL are also expected to see a reduction in exacerbations
and mortality compared to no maintenance treatment,
though the mortality benefit is not as great as FSC. The
reduction in expected life years and QALYs for FP compared
with no maintenance treatment was driven by the higher
expected mortality rate from TORCH.11 Overall, patients
receiving FSC were expected to receive the greatest benefit
in terms of both exacerbation prevention and survival.
The incremental costs per QALY gained for FSC and SAL
(each compared to placebo) are less than the $50,000
threshold.30e32 Thus, based on the results of TORCH,
treatment with either would generally be regarded as cost-
effective when compared to no maintenance treatment
based on this threshold. Based on TORCH results, the
incremental cost per QALY gained for FSC compared to SALis $69,888. The incremental cost per QALY value would
generally be considered to be in the range of possible cost-
effectiveness, depending on a patients’ willingness to pay
for health gains in this disease area.30e32 However, this
incremental value should be interpreted with caution, as it
relates to the TORCH population who was not receiving any
type of maintenance therapy at the study outset. It should
therefore not be considered as representing the cost-
effectiveness of ‘switching’ from SAL to FSC. In addition, it
has been reported that many patients with moderate to
severe COPD in US health plans may not be receiving the
appropriate maintenance therapies,33,34 in which case the
cost-effectiveness of FSC and SAL compared to no mainte-
nance treatment is the most relevant comparison to
consider.
Sensitivity analysis indicates that the results are sensi-
tive to changes in FSC relative risk of mortality in patients
with moderate COPD and the duration of time over which
FSC has full efficacy. Variation of these parameters (one by
one) within their plausible ranges shows that the incre-
mental cost per QALY would in certain cases increase to
values greater than $50,000, but in all cases the value
remains below $72,000. Multivariate probabilistic sensi-
tivity analysis reported an incremental cost per QALY of less
than $50,000 in 77.6% of model iterations (i.e., probability
of FSC being cost-effective compared with no maintenance
treatment using this threshold).
As with most model-based cost-effectiveness analysis,
a number of assumptions were necessary due to lack of
available published clinical data. For example, we did not
differentiate exacerbation rate ratios or mortality hazard
ratios by disease severity. The risk of exacerbation and
mortality varies at different stages of COPD severity, and it
is possible that the risk reduction with treatment may be
greater in more severe COPD. However, since these data
were unavailable, the hazard ratio for the entire COPD
population in the trial was used. Assuming a constant rate
reduction irrespective of disease severity is likely to be
a conservative assumption.
In the analysis, the base probability of exacerbation in
each COPD severity group was assumed to be the same
(based on available data from TORCH). This may not be the
case in the real world as there is evidence that exacerba-
tions become more common as COPD worsens. As a result,
we performed a subsequent analysis in which we adjusted
the base probability of exacerbation as seen in Sin et al.13
to account for differences in exacerbation rate across
COPD severity groups. In this analysis, the incremental cost
per QALY was found to be $34,845 which is nearly identical
to that of the base case scenario. Thus, varying exacer-
bations by disease severity did not significantly affect the
results.
A limitation of this analysis is that the clinical data used
in the model are based on a 3-year clinical trial. It is
unclear exactly what effect the COPD treatments will have
on exacerbation and mortality risks beyond 3 years, and the
sensitivity analysis on duration of drug efficacy over time
indicated that this is an important assumption to consider.
Results vary substantially when the duration of full efficacy
was varied. As such, further research is needed to examine
clinical effectiveness beyond the time frame of the TORCH
study.
Table 3 Results of base case analysis.
Outcome Placebo Advair 500/50 Fluticasone propionate Salmeterol
Total costs $18,986 $42,019 $23,727 $29,439
Drug $0 $25,045 $7341 $12,725
Other medical $18,986 $16,974 $16,387 $16,715
Life years 9.15 10.09 8.91 9.84
QALYs 6.74 7.42 6.58 7.24
Number of exacerbations
Moderate 9.29 7.45 8.31 8.49
Severe 1.88 1.70 1.61 1.64
Total 11.17 9.15 9.92 10.14
Number of hospital days 10.51 9.53 9.03 9.20
Number of symptom-free days 3258.09 3638.71 3188.18 3533.80
Incremental cost
per life year gained
e $24,530 Dominated $15,098
Incremental cost
per QALY gained
e $33,865 Dominated $20,797
Incremental cost
per Exac. avoided
e $11,405 $3796 $10,152
Incremental cost
per hospital day avoided
e $23,456 $3197 $8007
Incremental cost
per symptom-free day gained
e $61 Dominated $38
Cost-effectiveness of fluticasone propionate/salmeterol 19As with any modeling exercise using clinical trial data,
the patient population may not be representative of
a treatable ‘real world’ population. Decision-makers should
be cautious when interpreting these results if they have
reason to believe that the treatable population in their
region or health care plan differs substantially from that
investigated in TORCH as they may not be directly appli-
cable to patients in a particular region.
As with previous modeling studies, limitations in the
assumptions around disease progression have been made.
Specifically, we assume a constant transition probability
over time. However, it is possible that the patients most
likely to transition to a more severe health state will do so
early (biological variability, more aggressive disease), and
that over time fewer patients will transition because they
are truly healthier patients. We also do not differentiate
transition probabilities based on drug treatment, though
recent clinical trial results suggest that FSC may provide
a benefit in rate of decline of FEV1 for patients with
COPD.35 At the time of this analysis, a constant and equal
rate of decline for all comparators was assumed due to lack
of available data in the form necessary for inclusion in this
analysis. Celli et al.23 have recently reported significant
changes in annual rate of decline in percent predicted FEV1
for each treatment group in TORCH (Table 3 of Celli et al.).
When exploring the potential impact that this differential
rate of decline by treatment has on the results, the cost-
effectiveness of both FSC and SAL improves (i.e., lower
ICER values) compared to no maintenance treatment, and
the cost-effectiveness of FSC compared to SAL also
improves.
With limited health care resources, it is important to
allocate resources to interventions that are most cost-effective (i.e., have the greatest benefit per cost). Cost-
effectiveness modeling exercises enable decision-makers to
examine the effects of a new therapy and its potential
impact on costs and quality of life in a scientifically rigorous
and reproducible manner. This study suggests that treat-
ment with FSC for patients with COPD is cost-effective
compared to no maintenance treatment. Patients receiving
FSC incur greater total costs. However, these costs are also
associated with a reduction in exacerbations experienced
and an improvement in life expectancy and QALYs. One of
the strengths of this study is that it is the first model to
consider drug-specific mortality risk reduction in COPD.
While this study provides the first published estimates of
the cost-effectiveness of COPD treatment when considering
mortality benefits, future studies should prospectively
follow patients on COPD treatments in order to stratify
efficacy by COPD severity.Acknowledgements
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